Halozyme Therapeutics Inc.

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

39.25%

Market Cap

4.64 Bil.

P/E Ratio

26.31

Dividend Yield

0.00 %

Earnings per Share

2.27 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE71.06 G0 Units
PRICE DETERMINATION TIME07/23/2026 / 09:17:23 PM
DAILY VOLUME (UNITS)70
DAILY HIGH / LOW71.0667.32
PREV. DAY'S PRICE68.12 (07/22)
CHANGE DAY BEFORE
+2.94
4.32 %
52 WEEK HIGH / LOW71.64 (07/07)48.97 (07/23)
More Price Information

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
1.943.172.277.118.74
DIVIDENDS PER SHARE
0.000.000.00--
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
17.6113.9326.319.697.88
PRICE - BOOK RATIO
55.9116.18162.39--
PRICE - SALES RATIO
5.986.095.97--
PRICE - CASH FLOW RATIO
12.7612.9212.80--
Further Key Figures

Master Data

WKN
A0DLHS
ISIN
US40637H1095
SYMBOL
RV7
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
HALOZYME THERAPEU.DL-,001
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
US Dollar
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
126.83 Mil.
MARKET CAPITALISATION
4.64 Bil.

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
3.18 %
12.93 %
16.76 %
12.45 %
39.25 %
76.39 %
87.14 %
16.96 %
HIGH69.3671.6471.6471.6471.6471.6471.6471.64
LOW65.6459.4653.3853.0648.9730.5027.3253.06

Dividende

pro Aktie
HALOZYME THERAPEU.DL-,001 does not deliver dividend information

Company profile

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.